​

Apogee Therapeutics (APGE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

APGE Stock Forecast

Apogee Therapeutics (APGE) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $109.44, with a high of $140.00 and a low of $83.00. This represents a 32.03% increase from the last price of $82.89.

- $30 $60 $90 $120 $150 High: $140 Avg: $109.44 Low: $83 Last Closed Price: $82.89

APGE Stock Rating

Apogee Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

APGE Price Target Upside V Benchmarks

TypeNameUpside
StockApogee Therapeutics32.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1311
Avg Price Target$140.00$106.00$104.91
Last Closing Price$82.89$82.89$82.89
Upside/Downside68.90%27.88%26.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-143--17
Mar, 26-142--16
Feb, 26-142--16
Jan, 26113---14
Dec, 25111---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 01, 2026Qize DingRedburn Partners$140.00$82.8968.90%68.90%
Mar 17, 2026Danielle BrillTruist Financial$83.00$69.8518.83%0.13%
Feb 02, 2026Akash TewariJefferies$95.00$65.9943.96%14.61%
Jan 22, 2026RBC Capital$83.00$81.911.33%0.13%
Jan 07, 2026Craig-Hallum$116.00$78.2048.34%39.94%
Jan 06, 2026BTIG$137.00$76.7878.43%65.28%
Jan 06, 2026Stifel Nicolaus$133.00$76.3474.22%60.45%
Dec 16, 2025Stephens$95.00$74.7827.04%14.61%
Dec 09, 2025Deutsche Bank$103.00$74.7537.79%24.26%
Nov 03, 2025Craig-Hallum$109.00$56.6392.48%31.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 24, 2026Deutsche BankBuyBuyhold
Mar 24, 2026CitigroupBuyBuyhold
Mar 24, 2026GuggenheimBuyBuyhold
Mar 02, 2026RBC CapitalSector PerformSector Performhold
Feb 02, 2026JefferiesBuyBuyhold
Jan 25, 2026UBSBuyBuyhold
Jan 25, 2026CitigroupBuyBuyhold
Jan 22, 2026RBC CapitalOutperformSector Performdowngrade
Jan 07, 2026Craig-HallumBuyBuyhold
Jan 07, 2026Wolfe ResearchPeer Performinitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.66$-3.30$-4.22---
Avg Forecast$-3.26$-3.10$-4.32$-5.36$-6.49$-7.03
High Forecast$-1.93$-2.90$-3.38$-3.52$-4.30$-7.03
Low Forecast$-3.85$-3.32$-4.77$-10.81$-12.46$-7.03
Surprise %-49.08%6.45%-2.31%---

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast------
High Forecast------
Low Forecast------
Surprise %------

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.98M$-182.15M----
Avg Forecast$-83.98M$-77.65M$-101.84M$-179.14M$-209.56M$-175.70M
High Forecast$-48.25M$-72.39M$-84.47M$-87.90M$-107.52M$-175.70M
Low Forecast$-96.19M$-82.91M$-119.20M$-270.39M$-311.60M$-175.70M
Surprise %-134.57%----

APGE Forecast FAQ

Is Apogee Therapeutics stock a buy?

Apogee Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Apogee Therapeutics is a favorable investment for most analysts.

What is Apogee Therapeutics's price target?

Apogee Therapeutics's price target, set by 10 Wall Street analysts, averages $109.44 over the next 12 months. The price target range spans from $83 at the low end to $140 at the high end, suggesting a potential 32.03% change from the previous closing price of $82.89.

How does Apogee Therapeutics stock forecast compare to its benchmarks?

Apogee Therapeutics's stock forecast shows a 32.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Apogee Therapeutics over the past three months?

  • April 2026: 0% Strong Buy, 82.35% Buy, 17.65% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 87.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 87.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Apogee Therapeutics’s EPS forecast?

Apogee Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-5.36, marking a 27.01% increase from the reported $-4.22 in 2025. Estimates for the following years are $-6.49 in 2027, and $-7.03 in 2028.

What is Apogee Therapeutics’s revenue forecast?

Apogee Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, and $0 for 2028.

What is Apogee Therapeutics’s net income forecast?

Apogee Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-179M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $-210M in 2027, and $-176M in 2028.